Cardinal Point Capital Management’s State Street SPDR S&P Biotech ETF XBI Stock Holding History
Bought
Maintained
Sold
Other funds holding XBI
ACA
Cardinal Point Capital Management's XBI Position: Q4 2025 in Review
Cardinal Point Capital Management sold out of State Street SPDR S&P Biotech ETF (XBI) in Q4 2025, closing a stake of 1,919 shares — an estimated $202K sold.
Cardinal Point Capital Management first reported a position in XBI in Q3 2025 and held it in 1 quarter. The position peaked at $202K in Q3 2025. 815 funds tracked by Wall St. Rank hold XBI as of Q4 2025.
- Cardinal Point Capital Management reported no remaining State Street SPDR S&P Biotech ETF position as of Q4 2025 after selling out during the quarter.
- Cardinal Point Capital Management sold 1,919 State Street SPDR S&P Biotech ETF shares in Q4 2025, an estimated $202K.
- Cardinal Point Capital Management first reported a position in State Street SPDR S&P Biotech ETF in Q3 2025 and held it in 1 quarter.
- Cardinal Point Capital Management's State Street SPDR S&P Biotech ETF position peaked at $202K in Q3 2025.
- 815 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q4 2025.
Based on Cardinal Point Capital Management's 13F filing for Q4 2025, filed 5 Feb 2026.